Overcoming IL-18BP Inhibition Service
The therapeutic challenge of interleukin-18 (IL-18) is not its potency, but its inhibition by the high-affinity decoy receptor, IL-18 binding protein (IL-18BP), which is consistently overexpressed in the tumor microenvironment (TME). Creative Biolabs' precision blockade strategy is designed to solve this critical problem. We create therapeutic agents that specifically target and bind IL-18BP with superior affinity. This competitive displacement mechanism is the key to unleashing the vast reservoir of endogenous, pre-complexed IL-18 already present at the tumor site, providing a safer and highly potent approach to immunotherapy.
Background What We Can Offer Workflow Why Choose Us FAQs Customer Review Related Services Contact Us
The Challenge: A High-Potential Cytokine Locked in the TME
The therapeutic promise of pro-inflammatory IL-18 is undeniable, yet its clinical translation has been thwarted by poor pharmacokinetics and its endogenous inhibitor, IL-18BP. IL-18BP acts as a master immunological brake, binding IL-18 with picomolar affinity and rendering it inactive. Critically, IL-18 is consistently overexpressed in the TME, resulting in abundant but functionally inert IL-18. This paradigm shift dictates that the future of IL-18 therapy lies not in adding more recombinant cytokine, but in unleashing the vast reservoir of endogenous, pre-complexed IL-18 already present at the tumor site.
Deliverables Focused on TME-Localized Efficacy
By focusing activation directly within the TME where IL-18BP is abundant, the resulting immune response is inherently localized, avoiding the systemic toxicity that plagued earlier IL-18 clinical efforts. Our service ensures the lead candidate functions as a targeted immunological accelerator, leading to profound CD8+ T-cell and NK-cell responses. Specific deliverables include:
-
Validated Sub-Picomolar Lead Candidates
Antibodies confirmed to possess the fierce affinity required to outcompete the natural IL-18 ligand.
-
Functional Proof of IFN-γ Induction
Data confirming enhanced IFN-γ secretion from TILs and NK cells under TME-mimicking conditions.
-
Synergistic Combination Data
Optimized dosing and scheduling data supporting the candidate's use in combination with immune checkpoint inhibitors (ICIs).
Discover How We Can Help – Request a Consultation to discuss your specific target affinity requirements and preclinical needs.
Workflow
Our rigorous workflow is engineered for precision and predictability, ensuring the lead candidate meets the uncompromising affinity and functional requirements necessary for clinical success. Every stage is optimized to manage the high-risk technical challenges associated with the IL-18BP target.
Why Choose Us?
Creative Biolabs distinguishes itself by mastering the critical challenge of achieving sub-picomolar affinity to fiercely outcompete the natural IL-18:IL-18BP bond. We utilize proprietary platforms like the kinetic exclusion assay (KinExA) screening technology, which is superior to standard surface plasmon resonance (SPR) for accurately measuring ultra-high affinity binding kinetics in solution, ensuring your candidate is a true functional blocker. Furthermore, we deploy specialized TME mimicry assays to replicate the low pH and hypoxic stress of the tumor microenvironment, ensuring the lead candidate remains potent in vivo and preventing the systemic toxicity that plagued earlier IL-18 efforts.
Experience the Creative Biolabs Advantage – Get a Quote Today to see how our precision affinity and TME validation can de-risk your program.
FAQs
Q1: How does this blockade strategy compare functionally to developing an IL-18 receptor agonist?
A1: While IL-18 receptor agonists (mimetics) bypass IL-18BP, our blockade strategy utilizes the body's natural, endogenous IL-18. This approach leverages the complex, multi-component signaling cascade of the natural cytokine.
Q2: Can Creative Biolabs assist with generating humanized versions of the identified lead candidates?
A2: Absolutely. Our service is designed for translational success. Once a potent lead candidate is identified and validated through our functional assays, we seamlessly transition the project into our dedicated antibody humanization.
Q3: Do you offer services to test the IL-18BP blocker against different tumor types or specific patient samples?
A3: Yes. We have extensive capabilities for custom assay development using patient-derived materials, including TILs and tumor fragments. This level of customization ensures the functional data generated is highly relevant to your specific oncology indication.
Customer Reviews
-
Localized Activation Confirmation
The TME mimicry assays confirmed activation only in low pH/hypoxia conditions, suggesting a reduced risk of systemic cytokine storm compared to the recombinant IL-18 muteins we previously tested. – Dr. Je*Willis
-
Optimized Combination Strategy
The service identified that our lead IL-18BP blocker showed robust synergy with anti-CTLA-4, generating a 5-fold higher IFN-γ output than the anti-PD-1 combination, which directed our preclinical efforts toward the optimal ICI partner. – Ax*Va
Related Services
To ensure the comprehensive success of your IL-18BP targeting program, Creative Biolabs recommends these complementary services:
Bispecific Antibody Engineering
Creative Biolabs is a leading supplier of antibody engineering and optimization, offering comprehensive services including bispecific antibody production, affinity maturation, and scFv/Fab formats design for immunotherapy.
Learn More →
Immune Checkpoint Blocking (ICB) Therapy Development
Creative Biolabs provides full-range ICB services—from target identification and validation to drug screening and preclinical testing—to develop new cancer immunotherapies.
Learn More →
How to Contact Creative Biolabs
Creative Biolabs possesses the specialized expertise and proprietary platforms required to navigate the technical demands of the IL-18BP: IL-18 axis, transforming this immunological roadblock into a major therapeutic opportunity.
Contact our specialist team today to design a bespoke IL-18BP inhibition service program.
